What's New for the Patient With ER+/HER2- MBC Progressing on CDK 4/6 Inhibitor Therapy? Expert Perspectives on 2023 Updates From San Antonio

Aditya Bardia, MD - Endocrine Sensitivity in the Real World: Practical Guidance to Optimize Second-Line Care in ER-Positive, HER2-Negative Advanced Breast Cancer: Please visit answersincme.com/GTJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. by CME in Minutes: Education in Oncology & Hematology

20 min listen

HER2-Positive Metastatic Colorectal Cancer: Unraveling Game-Changing Treatment Approaches: Listen to the experts as they share the latest findings on HER2-directed therapies in the treatment of HER2-positive metastatic colorectal cancer (mCRC). Credit available for this activity expires: 2/28/2025 Earn Credit / Learning... by Keeping Current

36 min listen

Sara M. Tolaney, MD, MPH - New Advances and Opportunities for Improvement in HR+/HER2- Early Breast Cancer: Practical Strategies for Optimal Clinical Integration of Adjuvant CDK4 and 6 Inhibitor Therapy: Go online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. by PeerView Internal Medicine CME/CNE/CPE Audio Podcast

29 min listen

Evolving Landscape of HR-Positive Metastatic Breast Cancer: A Year in Review: Join the experts for an in-depth update on hormone receptor (HR)-positive metastatic breast cancer (MBC). Credit available for this activity expires: 3/1/25 Earn Credit / Learning Objectives & Disclosures: by Keeping Current CME

76 min listen

Richard Finn, MD - Real Talk About CDK4/6 Inhibitors in the Treatment of HR+/HER2- Advanced Breast Cancer: Using Real-World Evidence to Impact Patient Outcomes: Please visit answersincme.com/WWC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. by CME in Minutes: Education in Oncology & Hematology

16 min listen

Multidisciplinary Team Best Practices to Improve Adherence for High-Risk, HR-Positive/HER2-Negative Early Breast Cancer: Cases From the Community: What are your strategies to improve adherence in patients with high-risk, HR-positive/HER2-negative early breast cancer? Credit available for this activity expires: 1/9/25 Earn Credit / Learning Objectives & Disclosures: by Keeping Current CME

31 min listen

Aditya Bardia, MD, MPH - Navigating the Shifting Treatment Paradigm in ER+/HER2- Breast Cancer: Harnessing Modern Treatment Options and the Expanding Evidence Base to Better Patient Care and Outcomes in Early and Advanced Disease: Go online to PeerView.com/KVE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. by PeerView Internal Medicine CME/CNE/CPE Audio Podcast

57 min listen

Latest Update on HER2-Low Breast Cancer and Implications for Clinical Practice: Did you know that patients with HER2-low metastatic breast cancer now have approved treatment options? Join for a discussion on trial data and testing. Credit available for this activity expires: 12/5/24 Earn Credit / Learning Objectives &... by Keeping Current CME

21 min listen

Joyce O’Shaughnessy, MD - Raising the Bar in HR+/HER2- Early Breast Cancer: Multidisciplinary Strategies for Integrating the CDK4 and 6 Inhibitors: Go online to PeerView.com/HYM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. by PeerView Internal Medicine CME/CNE/CPE Audio Podcast

69 min listen

Evolving Perspectives on HR-Positive Metastatic Breast Cancer: Current Understanding and New Insights: Are you up to date on the latest developments in hormone receptor-positive metastatic breast cancer? Listen to our expert panel to find out more! Credit available for this activity expires: 05/20/25 Earn Credit / Learning Objectives &... by Keeping Current

35 min listen

For Pharmacists: Evolution of HER2-Targeted Therapy in Gastroesophageal Adenocarcinoma: Did you know that HER2-targeted therapy is an established treatment option for patients with HER2-positive metastatic gastric/gastroesophageal junction (GEJ) cancer? Credit available for this activity expires: 4/16/25 Earn Credit / Learning Objectives... by Keeping Current CME

29 min listen

Evolving Paradigms of Hormone Receptor-Positive Breast Cancer: The Rise of Antibody-Drug Conjugates: Are you up to date on the latest clinical trial data on antibody-drug conjugates (ADCs) in hormone receptor (HR)-positive advanced breast cancer? Credit available for this activity expires: 11/20/23 Earn Credit / Learning Objectives &... by Keeping Current

71 min listen

Managing the Borderline-Risk Patient With Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Shedding Light on the Role of Surgeon, Radiologist, and Oncologist: Do you consult with the multidisciplinary team (MDT) when making treatment decisions for patients with hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC)? Credit available for this activity expires: 11/21/24 Earn Credit / Learning... by Keeping Current CME

28 min listen

Erika Hamilton, MD - How to Harness Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast Cancer: New Goals and Better Tools to Close the Gaps: Go online to PeerView.com/WFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. by PeerView Internal Medicine CME/CNE/CPE Audio Podcast

59 min listen

Sara M. Tolaney, MD, MPH - Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast Cancer: Go online to PeerView.com/VMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. by PeerView Internal Medicine CME/CNE/CPE Audio Podcast

55 min listen

Adam Brufsky, MD, PhD - Getting Real With Patients During Clinical Decision-Making: The Value of Sharing Real-World Evidence About CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast Cancer: Please visit answersincme.com/VVM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. by CME in Minutes: Education in Oncology & Hematology

17 min listen

Understanding the Concerns and Challenges of Patients With HR-Positive/HER2-Negative EBC: Expert Insights and Recommendations: How well do you understand the challenges that patients face with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer with a high risk for recurrence? Credit available for this activity expires:... by Keeping Current CME

26 min listen

Current and Emerging Therapies for CKD-Associated Pruritus: Join Dr Kremer and Dr Fishbane, experts in CKD-aP, as they lay out a clear path to helping these patients and improve their QoL. https://www.medscape.org/viewarticle/945887?src=mkm_podcast_addon_945887 by Keeping Current

38 min listen

Assessing Current and Emerging Options for the Management of Peripheral T-Cell Lymphoma: Join our expert faculty to learn more about current strategies and newer options for the treatment of peripheral T-cell lymphoma. Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/944034?src=mkm_podcast_addon_944034 by Keeping Current CME

36 min listen

Opportunities and Challenges in Early Breast Cancer: Do PARP Inhibitors Have a Role?: Dr Curigliano and Dr Loi discuss the latest clinical data regarding the use of PARP inhibitors in early high-risk breast cancer. Credit available for this activity expires: 7/29/2022 Earn Credit / Learning Objectives & Disclosures: by Keeping Current

27 min listen

Erika Hamilton, MD - Clarifying the Complexities of the Expanding Treatment Options for Advanced- and Early-Stage HR+/HER2- Breast Cancer: Go online to PeerView.com/YNC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. by PeerView Internal Medicine CME/CNE/CPE Audio Podcast

101 min listen

Antibody-Drug Conjugates in the Spotlight: Novel Strategies for Breast Cancer Management: Are you up to date on the key clinical data on ADCs in breast cancer -- especially those that set the stage for upcoming data releases? Credit available for this activity expires: 5/31/2024 Earn Credit / Learning Objectives & Disclosures: by Keeping Current

38 min listen

Connecting With the Experts at ASCO 2024: Clinical Pearls and Data Insights About Anti-HER2 Therapies in Biliary Tract Cancer: Get the latest data from ASCO 2024 about anti-HER2 therapies in biliary tract cancer. Credit available for this activity expires: 6/25/25 Earn Credit / Learning Objectives & Disclosures: by Keeping Current CME

24 min listen

Hope S. Rugo, MD, FASCO - Stay in the Know About HER2-Low: Improving Breast Cancer Outcomes with Emerging Antibody Drug Conjugates: Please visit answersincme.com/PHE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. by CME in Minutes: Education in Oncology & Hematology

14 min listen

Stuart J. Schnitt, MD - A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer: Exploring the Biology and Updating Best Practices for Testing and Treatment: Go online to PeerView.com/NRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. by PeerView Internal Medicine CME/CNE/CPE Audio Podcast

85 min listen

What's New in the Treatment of Gastroesophageal Reflux Disease and Erosive Esophagitis: Spring Meeting Updates: Hear from 3 experts as they discuss the latest clinical knowledge on the management of gastroesophageal reflux disease (GERD) and erosive esophagitis. Credit available for this activity expires: 6/11/25 Earn Credit / Learning Objectives & Disclosures: by Keeping Current CME

73 min listen

Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer: The Great Debate: What strategies are you using to individualize treatment of HR+/HER2- early breast cancer? Credit available for this activity expires: 11/17/24 Earn Credit / Learning Objectives & Disclosures: by Keeping Current CME

32 min listen

Evolution of HER2-Targeted Therapy in Gastroesophageal Adenocarcinoma: Did you know that HER2-targeted therapy is an established treatment option for patients with HER2-positive metastatic gastric/gastroesophageal junction (GEJ) cancer? Credit available for this activity expires: 3/29/25 Earn Credit / Learning Objectives... by Keeping Current CME

29 min listen

S05 E08 - ASCO 2022: When The Dust Settles, What Are My Treatment Options For ER+/HER2- MBC? by Our MBC Life

63 min listen

Latest Advances in Systemic Treatment for Breast Cancer: Evidence and Implications: Are you up to date with developments in breast cancer? Join the specialists for the data most recently presented at the American oncology meeting. Credit available for this activity expires: 6/30/24 Earn Credit / Learning Objectives & Disclosures: by Keeping Current

41 min listen

Discover this podcast and so much more

What's New for the Patient With ER+/HER2- MBC Progressing on CDK 4/6 Inhibitor Therapy? Expert Perspectives on 2023 Updates From San Antonio

What's New for the Patient With ER+/HER2- MBC Progressing on CDK 4/6 Inhibitor Therapy? Expert Perspectives on 2023 Updates From San Antonio

Description

Titles in the series (100)

More Episodes from Keeping Current

Related podcast episodes